ASS1 and glioblastoma: Our study provides compelling evidence that arginine deprivation combined with IR is a promising immunotherapeutic strategy for the treatment of ASS1+ GBM, which operates by enhancing the production of cytotoxic levels of peroxynitrite and selectively modulating GAMM to become tumor attacking.